Medical/Pharmaceuticals
Innovent Announces Primary Endpoint Met in the Phase 3 Clinical Trial (RESTORE-1) of IBI311 (Anti-IGF-1R Antibody) in Treating Thyroid Eye Disease and Plans to Submit NDA to the NMPA
ROCKVILLIE, MD. and SUZHOU, China, Feb. 20, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major di...
2024-02-20 08:22
3951
HKUST Neuroscientists Develop Highly Accurate Universal Diagnostic Blood Test for Alzheimer's Disease and Mild Cognitive Impairment
At a glance: * Remarkably high accuracy rate – over 96% for AD and 87% for MCI; * Applicable across diverse ethnic populations, including Chinese and European; * Enables early detection of AD and subsequent progression; * Captures multiple AD-associated biological pathways; * A game-chan...
2024-02-19 20:18
2030
Neurophth Announces Completion of Patient Enrollment for Opvika® Phase I/II Clinical Trial in the U.S.
WUHAN, China and SAN DIEGO, Feb. 19, 2024 /PRNewswire/ -- Neurophth Therapeutics, Inc. ("Neurophth") announced today thatthe last patient has been enrolled in Phase I/II clinical trial of Opvika® (Esonadogene Imvoparvovec) for the treatment of Leber hereditary optic neuropathy caused byND4 mutati...
2024-02-19 19:30
1514
SIBIONICS Announced to Exhibit at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)
The company will be hosting an influencer meeting during the conference LOS ANGELES, Feb. 19, 2024 /PRNewswire/ -- SIBIONICS, the world's third-largest Continuous Glucose Monitoring (CGM) System brand, announced the company will be exhibiting at the International Fair of New Technologies in Diab...
2024-02-19 10:55
2209
AffaMed Therapeutics Announces New Drug Application Acceptance by Singapore Health Sciences Authority (HSA) for DEXTENZA® for Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery, and Ocular Itching Associated with Allergic Conjunctivitis
SHANGHAI, Feb. 19, 2024 /PRNewswire/ -- AffaMed Therapeutics ("AffaMed"), a biotechnology company dedicated to developing and commercializing transformative pharmaceutical, and surgical products that address critical unmet medical needs in ophthalmology, today announced that the Singapore Health ...
2024-02-19 09:00
3538
Everest Medicines Announces Termination of Collaboration Agreements with Providence
-Everest will continue to develop self-discovered products utilizing the mRNA platform- SHANGHAI, Feb. 19, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative...
2024-02-19 08:20
2067
SwiftMR™, Game-Changing AI-Powered MRI Solution Gears Up in ANZ Market: AIRS Medical Forges Strategic Partnership with ParagonCare
SEOUL, South Korea, Feb. 19, 2024 /PRNewswire/ -- AIRS Medical Inc., a leading provider of AI-powered healthcare solutions, has announced a strategic partnership agreement with ParagonCare Limited(ASX: PGC), a premier provider of healthcare technology, devices, software, and consumables inAustral...
2024-02-19 06:00
2146
Jacobio Announces China CDE Clearance for Phase III Clinical Trial of SHP2 Inhibitor Plus KRAS G12C Inhibitor
BEIJING and SHANGHAI and BOSTON, Feb. 18, 2024 /PRNewswire/ -- Jacobio Pharma (1167.HK), a clinical-stage oncology company drugging the undruggable targets, today announced it received approval of registrational phase III clinical trial of the combination therapy between its novel KRAS G12C inhib...
2024-02-18 20:50
2543
China Medical University Hospital (CMUH) in Taiwan Upgrades Smart Healthcare with Gen AI
Establishing a comprehensive "AI-assisted Physician" using generative AI from Google Cloud, including MedLM TAICHUNG, Feb. 17, 2024 /PRNewswire/ -- China Medical University Hospital (CMUH) inTaiwan announced its collaboration with Google Cloud in mid-December 2023. Using Google Cloud's generativ...
2024-02-17 21:30
5932
New Study Demonstrates Predictive Value of Lunit SCOPE IO to Predict Outcomes of Immune Checkpoint Inhibitor Therapy Across Diverse Tumors - published in the JITC
- A new study published in the Journal for ImmunoTherapy of Cancer (JITC) shows that Lunit's AI-powered biomarker "Lunit SCOPE IO" can predict favorable outcomes of Inflamed Immune Phenotype patients treated with Immune Checkpoint Inhibitor across multiple cancer types SEOUL, South Korea, Feb. ...
2024-02-16 22:03
5197
IFPA Releases an Innovative Psoriatic Care Roadmap and Action Playbook
STOCKHOLM, Feb. 16, 2024 /PRNewswire/ -- IFPA Forum Asia 2023, held in Singapore , brought together a diverse group of stakeholders, including patient advocates, their associations, family members, policymakers, healthcare professionals, and the private sector. Held inSingapore, the forum served a...
2024-02-16 17:00
7752
Kim Byoung Joon LEDAS Varicose Vein Clinic Becomes the First Organization to be Accredited under GHA Standards for Medical Travel 5.0
PALM BEACH GARDENS, Fla., Feb. 15, 2024 /PRNewswire/ -- In a significant achievement that firmly underscores its commitment to the highest standards of healthcare, Kim Byoung Joon LEDAS Varicose Vein Clinic ( https://www.kbjledas.com/) in Busan, South Korea, has been awarded the distinguished Acc...
2024-02-15 19:00
2164
Pierre Fabre Laboratories and the EspeRare Foundation to be honored with the EURORDIS Company Award for Patient Engagement 2024, in their approach to co-developing a treatment for XLHED.
CASTRES, France and GENEVA, Feb. 15, 2024 /PRNewswire/ -- On February 20, International Ectodermal Dysplasias Awareness Day, Pierre Fabre Laboratories and the EspeRare Foundation will receive the EURORDIS Company Award for Patient Engagement 2024, at the EURORDIS Black Pearl Award Ceremony to be ...
2024-02-15 17:05
2092
Pharus Diagnostics Signs Worldwide Exclusive License Agreement with City of Hope for Novel Biomarkers to Be Used in Liquid Biopsy Screening for Early Pancreatic Cancer Diagnosis
LOS ANGELES, Feb. 15, 2024 /PRNewswire/ -- Pharus Diagnostics ("PharusDx") today announced a global exclusive license agreement with City of Hope cancer center for proprietary biomarkers to be used in early screening of individuals at risk for pancreatic ductal adenocarcinoma (PDAC). This license...
2024-02-15 16:05
2123
iNtRON, Development of PHAGERIA® Anti-Cancer Candidate with Enhanced Antimicrobial Activity by Robot Bacteriophage platform technology
▶ Robot Bacteriophage against microbiome associated with colorectal cancer ▶ Bacteriophage Improvement Platform technology with a broad antimicrobial activity ▶ Proprietary Technology incorporating CRISPR/Cas Technology BOSTON, Feb. 14, 2024 /PRNewswire/ -- iNtRON Biotechnology ("iNtRON", www.i...
2024-02-15 11:37
1598
STARmed to Accelerate Global Market Entry of EUSRA and ELRA Products through Olympus
SEOUL, South Korea, Feb. 14, 2024 /PRNewswire/ -- STARmed, a leading developer
and manufacturer of medical devices for tumor ablation, today announced global
market expansion of its EUSRA and ELRA products, throughOlympus
2024-02-14 22:00
1166
Sky Labs' CART BP Becomes the World's First to Complete Comparative Studies with All Blood Pressure Measurement Methods
- The only cuffless blood pressure monitor to complete comparative studies with three types of existing blood pressure measurement methods and prove even accuracy - 24-hour Ambulatory Blood Pressure Monitoring is the first pilot research to reflect ESH recommendations in 2023 SEOUL, South K...
2024-02-14 21:00
1663
YS Biopharma Announces Appointment of New Directors
GAITHERSBURG, Md., Feb. 14, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (Nasdaq: YS) ("YS Biopharma" or the "Company", and together with its subsidiaries, "YS Group"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccin...
2024-02-14 20:50
3667
GC Biopharma Presents Updates on its LSD Treatments at the WORLDSymposium 2024
* Recent updates on its development of LSD treatments were presented YONGIN, South Korea, Feb. 14, 2024 /PRNewswire/ -- GC Biopharma (CEO, Eun-Chul Huh), a South Korean biopharmaceutical company, announced onFeb. 14th that it has presented the development updates on its LSD (Lysosomal Storage D...
2024-02-14 16:33
1845
Brii Biosciences Announces Agreement to Acquire VBI's IP Rights in BRII-179 (VBI-2601) and Plans to Initiate Technology Transfer to Expand Clinical and Commercial Supplies
Acquiring all intellectual properties relating to BRII-179 and eliminating future milestone and royalty payments to VBI, subject to achievement of certain activities Transferring manufacturing technologies of BRII-179 and PreHevbrio/PreHevbri to additional manufacturing sites and expanding footp...
2024-02-14 08:07
4159
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 314 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
8288
Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
2024-11-20 09:00
7685